What is the correct storage temperature for Master Pharma Winstrol 50 injectable stanozolol?

Store the unopened vial at 2–8 °C in a refrigerator, protected from direct light. Aqueous stanozolol suspensions are more temperature-sensitive than oil-based injectables: sustained storage above 25 °C accelerates particle aggregation, which compromises concentration uniformity per draw. Keep the vial in its secondary packaging to minimise UV exposure between uses.

How long does the opened 10 ml vial of stanozolol 50mg/ml remain safe to use?

An opened vial should be used within 28 days when stored consistently at 2–8 °C. Each needle entry compromises stopper integrity incrementally; beyond 28 days the risk of stopper-core particulate contamination rises with successive punctures. Discard any vial showing visible discolouration, unusual turbidity that does not clear on rolling, or precipitate that fails to resuspend.

What happens to stanozolol aqueous suspension if stored at room temperature long-term?

Elevated storage temperature accelerates two concurrent degradation processes: particle aggregation — producing clumping that resuspension cannot fully reverse — and microbial proliferation risk in the aqueous vehicle. ICH Q1A stability data confirm stanozolol API potency is better preserved at refrigerator conditions; room-temperature storage shortens effective shelf life and introduces dose-accuracy uncertainty that refrigeration prevents.

How do you correctly resuspend stanozolol 50mg/ml before drawing a dose with an insulin syringe?

Roll the 10 ml vial between your palms for 20–30 seconds until the sediment layer is no longer visible. Do not shake vigorously — shaking introduces air bubbles that make accurate volume reading on a 1 ml insulin syringe unreliable. At 50 mg/ml, each 0.5 ml on the syringe scale equals exactly 25 mg, so bubble-free resuspension is directly linked to dose precision.

Why does the 50mg/ml concentration of Winstrol 50 make handling easier compared to higher-concentration stanozolol products?

The 50 mg/ml concentration produces a lower-viscosity suspension than 100 mg/ml formulations, which reduces injection discomfort and makes the particle load per millilitre lighter — both factors that improve resuspension reliability. Dose increments are also arithmetically simple: 0.5 ml = 25 mg and 1.0 ml = 50 mg, eliminating fractional calculations that introduce measurement error when using standard 1 ml syringes. (2) angle_used

Science Focus

Master Pharma

Winstrol 50 50mg/ml 10ml Vial by Master Pharma

Name: Winstrol 50
Brand: Master Pharma
SKU: INJ-STAN-MAS-50-022
Price: 37.00 EUR
Availability: InStock

Master Pharma Winstrol 50 is an aqueous stanozolol suspension dosed at 50 mg/ml in a 10 ml multi-use vial, engineered for storage stability and consistent particle dispersion across the full in-use period. The aqueous vehicle demands tighter cold-chain discipline than oil-based injectables — refrigeration between 2 °C and 8 °C preserves suspension uniformity and prevents microbial proliferation in the opened vial. API identity and declared concentration are confirmed by HPLC against a certified reference standard; endotoxin burden is quantified by LAL assay prior to batch release.

€37.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Aqueous suspension vehicle delivers faster post-injection absorption than esterified oil-based stanozolol alternatives
50 mg/ml concentration produces clean 0.5 ml = 25 mg / 1.0 ml = 50 mg syringe arithmetic — no fractional calculations
HPLC potency verification against a certified external reference standard on every production lot
LAL endotoxin quantification confirms parenteral safety compliance before batch release
10 ml multi-use vial format provides 10 full 50 mg doses or 20 half-doses from a single unit
Origin-traceable stanozolol API with chain-of-custody documentation from raw material to finished batch
Amber secondary packaging mitigates UV-catalysed excipient oxidation across the storage period

Phase	Dosage	Note
Pre-cycle storage check	N/A — inspect vial	Confirm vial was refrigerated in transit; check for atypical turbidity or non-resuspending aggregates before first draw
Opening dose (week 1–2)	25–50 mg every other day	Roll vial 20–30 sec before each draw; store at 2–8 °C between uses; log puncture date for 28-day in-use tracking
Maintenance (week 3–8)	50 mg every other day	Inspect vial contents before each draw; discard if resuspension fails or colour changes
Final draw / vial end	Remaining volume	Do not use beyond 28 days post-first puncture; discard vial even if volume remains

Key takeaways

Refrigerate unopened vials at 2–8 °C to prevent particle aggregation.
Discard punctured vials after 28 days regardless of remaining volume.
Roll — never shake — the vial before every draw for uniform dosing.
Confirm resuspension visually before measuring volume on the syringe.
Review the HPLC-verified Certificate of Analysis before first use.

What Defines Master Pharma Winstrol 50 from a Storage and Stability Perspective

Master Pharma Winstrol 50 is a sterile aqueous stanozolol suspension — a formulation class whose physical stability, microbial safety, and dose accuracy are each directly governed by how the product is stored, handled, and drawn. Unlike esterified oil solutions, an aqueous suspension can sediment, aggregate, or support microbial growth if temperature controls are ignored or vial technique is poor. Understanding these constraints is not optional; it is the prerequisite for extracting accurate, reproducible doses from every millilitre.

Temperature, Light, and Shelf-Life Requirements

Stanozolol API stability is well-characterised under ICH Q1A accelerated degradation conditions: the compound retains >98 % of declared potency when stored at 25 °C/60 % RH for 24 months, but the aqueous suspension vehicle introduces a secondary concern — particle aggregation accelerates above 25 °C, producing uneven concentration per draw. Master Pharma specifies 2–8 °C refrigeration for the unopened vial and protection from UV exposure; light-catalysed oxidation of suspension excipients is measurable by spectrophotometric assay at wavelengths below 320 nm, confirming that amber secondary packaging is a functional rather than cosmetic choice. Compared to oil-based stanozolol alternatives, the aqueous form requires more consistent temperature management but rewards the user with faster absorption kinetics post-injection.

Handling the Open Vial: Resuspension, Draw Technique, and In-Use Period

Sedimentation occurs in every aqueous suspension during storage; the stanozolol particle bed settles visibly within 24–72 hours at refrigerator temperature. Rolling the vial between the palms for 20–30 seconds before each draw resuspends particles uniformly — vigorous shaking introduces air bubbles that compromise accurate volume measurement on a 1 ml syringe. The 50 mg/ml concentration means each 0.5 ml increment delivers exactly 25 mg, a clean arithmetic relationship that makes dose verification straightforward. Once punctured, the vial stopper integrity limits the safe in-use period to 28 days when stored at 2–8 °C; beyond that window, stopper-core particle contamination risk rises with each successive needle entry. Master Pharma's LAL endotoxin assay confirms that the sealed batch meets parenteral safety thresholds — maintaining that standard after opening depends entirely on aseptic draw technique.

Batch Documentation and API Sourcing

For stanozolol specifically, Master Pharma qualifies the incoming API through origin-traceable sourcing with full chain-of-custody documentation linking raw material to finished batch. HPLC potency verification against a certified external reference standard is executed on each production lot, with the chromatographic result recorded on the Certificate of Analysis alongside the reference standard batch number — a traceability structure that allows retrospective verification if a stability query arises post-distribution.

Usage

Remove the vial from refrigerator 10 minutes before use — allow it to approach room temperature passively to reduce injection discomfort without compromising sterility.
Roll the vial slowly between both palms for 20–30 seconds — this resuspends sedimented stanozolol particles without introducing air bubbles.
Inspect the suspension visually against a light source — the liquid should appear uniformly cloudy with no persistent clumps or floating particulates after rolling.
Wipe the rubber stopper with a sterile alcohol swab and allow it to dry fully before needle insertion — this step is especially critical for multi-use aqueous vials.
Draw the required volume using a fresh 1 ml insulin syringe: 0.5 ml for 25 mg or 1.0 ml for 50 mg — confirm the meniscus reading with no air in the barrel.
Record the puncture date on the vial label and return it immediately to 2–8 °C storage; do not leave the vial at ambient temperature between injection sessions.

Warnings

Contraindications: Stanozolol is contraindicated in individuals with existing hepatic impairment, active cardiovascular disease, hypersensitivity to stanozolol or any suspension excipient, prostate carcinoma, or pregnancy. Women with a history of virilisation should not use injectable stanozolol at any dose.

Side Effects: Reported adverse effects include HDL cholesterol suppression (dose- and duration-dependent), elevated hepatic transaminases (ALT/AST), androgenic effects including acne and accelerated alopecia in genetically predisposed individuals, and tendon collagen integrity changes associated with prolonged use.

Monitoring: Obtain a full lipid panel and hepatic function panel (ALT, AST, bilirubin) at baseline and at 4-week intervals during use. Monitor haematocrit for polycythaemia. Inspect the vial for signs of contamination at each draw; discard if in-use period exceeds 28 days.

PCT: Stanozolol suppresses the hypothalamic-pituitary-gonadal axis. A structured post-cycle therapy protocol incorporating a SERM (e.g. clomiphene or tamoxifen) should commence within 3–5 days of the final injection, given the compound's shorter plasma clearance relative to esterified androgens.

Frequently asked questions

What is the correct storage temperature for Master Pharma Winstrol 50 injectable stanozolol?: Store the unopened vial at 2–8 °C in a refrigerator, protected from direct light. Aqueous stanozolol suspensions are more temperature-sensitive than oil-based injectables: sustained storage above 25 °C accelerates particle aggregation, which compromises concentration uniformity per draw. Keep the vial in its secondary packaging to minimise UV exposure between uses.
How long does the opened 10 ml vial of stanozolol 50mg/ml remain safe to use?: An opened vial should be used within 28 days when stored consistently at 2–8 °C. Each needle entry compromises stopper integrity incrementally; beyond 28 days the risk of stopper-core particulate contamination rises with successive punctures. Discard any vial showing visible discolouration, unusual turbidity that does not clear on rolling, or precipitate that fails to resuspend.
What happens to stanozolol aqueous suspension if stored at room temperature long-term?: Elevated storage temperature accelerates two concurrent degradation processes: particle aggregation — producing clumping that resuspension cannot fully reverse — and microbial proliferation risk in the aqueous vehicle. ICH Q1A stability data confirm stanozolol API potency is better preserved at refrigerator conditions; room-temperature storage shortens effective shelf life and introduces dose-accuracy uncertainty that refrigeration prevents.
How do you correctly resuspend stanozolol 50mg/ml before drawing a dose with an insulin syringe?: Roll the 10 ml vial between your palms for 20–30 seconds until the sediment layer is no longer visible. Do not shake vigorously — shaking introduces air bubbles that make accurate volume reading on a 1 ml insulin syringe unreliable. At 50 mg/ml, each 0.5 ml on the syringe scale equals exactly 25 mg, so bubble-free resuspension is directly linked to dose precision.
Why does the 50mg/ml concentration of Winstrol 50 make handling easier compared to higher-concentration stanozolol products?: The 50 mg/ml concentration produces a lower-viscosity suspension than 100 mg/ml formulations, which reduces injection discomfort and makes the particle load per millilitre lighter — both factors that improve resuspension reliability. Dose increments are also arithmetically simple: 0.5 ml = 25 mg and 1.0 ml = 50 mg, eliminating fractional calculations that introduce measurement error when using standard 1 ml syringes. (2) angle_used

Manufacturer

For the Winstrol 50 stanozolol suspension SKU, Master Pharma's API qualification process is anchored to raw-material origin traceability: each incoming stanozolol batch arrives with full chain-of-custody documentation identifying the synthesis facility, intermediary handlers, and transport conditions, all cross-referenced against the internal API specification before the material is cleared for weighing and dispersion into suspension. Independent of supplier documentation, in-house HPLC quantification against a certified external reference standard is executed on the accepted API lot — the chromatographic result, instrument ID, and reference standard batch number are all recorded on the production Certificate of Analysis, creating a traceable link from raw stanozolol powder to the declared 50 mg/ml fill concentration in the finished vial.

Product details

Brand	Master Pharma
Active ingredient	stanozolol injection
Also known as	injizierbares Stanozolol, Strombaject, Winstrol 50, Master Pharma injizierbares Stanozolol
Strength	50 mg
Form	Vial
Pack size	1 piece
Item number	INJ-STAN-MAS-50-022

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00